Brief: Syros Announces First Patient In Dose Confirmation Study Of SY-2101 In Acute Promyelocytic Leukemia

Syros Pharmaceuticals

29/09/2021 13:42

Sept 29 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS ANNOUNCES FIRST PATIENT IN DOSE CONFIRMATION STUDY
OF
SY-2101, A NOVEL ORAL FORM OF ARSENIC TRIOXIDE, IN ACUTE
PROMYELOCYTIC LEUKEMIA
    * SYROS PHARMACEUTICALS INC - CONFIRMATORY DOSE AND PK DATA
EXPECTED IN FIRST HALF OF 2022, WITH A PHASE 3 TRIAL EXPECTED TO
BEGIN IN 2022

Source text for Eikon:  ID:nBw2VHj5qa 
Further company coverage:  SYRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))